In addition to targeting epigenetic drugs, a SMAC mimetic (an IAP inhibitor) was shown to induce elevated expression of MHC-I through the TRAF3/NF-κB pathway, thereby enhancing the sensitivity of tumor cells to T cell-driven cytotoxicity [196]. Here, CD47 is linked to neoplasm.